Extended intervals using epoetin alfa in pre-dialysis patients with chronic kidney disease (CKD) appears to be limited to patients with low dose requirements.

被引：0
|
作者：
Wish, J
Law, AW
Schulman, KL
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Roche Labs Inc, Nutley, NJ USA
[3] Thomson Medstat, Cambridge, MA USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2006年 / 47卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
173
引用
收藏
页码：A62 / A62
页数：1
相关论文
共 50 条
  • [1] Extended dosing with darbepoetin alfa in pre-dialysis chronic kidney disease (CKD) appears to be limited to patients with low dose requirements
    Wish, J
    Law, AW
    Schulman, KL
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A61 - A61
  • [2] Epoetin alfa and darbepoetin alfa dosing trends in pre-dialysis chronic kidney disease patients
    Mody, S
    Padmanabhan, V
    McKenzie, S
    Piech, CT
    VALUE IN HEALTH, 2005, 8 (03) : 416 - 416
  • [3] Epoetin alfa and darbepoetin alfa dosing patterns in anemic pre-dialysis chronic kidney disease patients
    Mody, S
    Padmanabhan, V
    McKenzie, RS
    Bookhart, B
    VALUE IN HEALTH, 2006, 9 (03) : A96 - A96
  • [4] Alternate dosing strategies of epoetin alfa in pre-dialysis chronic kidney disease patients.
    Sarac, E
    Smavatkul, C
    Boolchand, V
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 794A - 794A
  • [5] Epoetin alfa and darbepoetin alfa dosing patterns and drug costs in patients with pre-dialysis chronic kidney disease
    Lefevbre, P
    Mody, SH
    McKenzie, RS
    Bookhart, B
    Duh, MS
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A39 - A39
  • [6] OBSERVATIONAL STUDY OF ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) CONVERTING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Lunde, Martin
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    Senbetta, Mekre
    McKenzie, R. Scott
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2011, 57 (04) : A60 - A60
  • [7] Epoetin alfa and darbepoetin alfa dosing trends and drug costs in elderly pre-dialysis chronic kidney disease patients
    Mody, S.
    Padmanabhan, V
    Bookhart, B.
    Mckenzie, R. S.
    VALUE IN HEALTH, 2007, 10 (03) : A12 - A13
  • [8] Homoarginine and Mortality in Pre-Dialysis Chronic Kidney Disease (CKD) Patients
    Ravani, Pietro
    Maas, Renke
    Malberti, Fabio
    Pecchini, Paola
    Mieth, Maren
    Quinn, Robert
    Tripepi, Giovanni
    Mallamaci, Francesca
    Zoccali, Carmine
    PLOS ONE, 2013, 8 (09):
  • [9] HEMATOLOGIC OUTCOMES AND DOSING PATTERNS IN ANEMIC PATIENTS WITH PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) SWITCHING FROM DARBEPOETIN ALFA (DARB) TO EPOETIN ALFA (EPO)
    Hura, Claudia
    Jackson, James
    Lunacsek, Orsolya
    Bailey, Robert A.
    McKenzie, R. Scott
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2010, 55 (04) : A65 - A65
  • [10] An examination of direct and indirect employer costs associated with epoetin alfa treatment in pre-dialysis chronic kidney disease patients
    Bookhart, Brahim K.
    Papatheofanis, Frank
    Chawla, Namrita
    Muser, Erik
    Piech, Catherine Tak
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2007, 49 (04) : A31 - A31
12345